Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD

European Respiratory Journal

Volumn 29, Issue 6, 2007, Pages 1115-1119

  Löfdahl, Claes Goran ^a   Postma, D S ^c   Pride, N B ^d   Boe, J ^e   Thoren A ^b  

^a LUND UNIVERSITY   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

Budesonide; Chronic obstructive pulmonary disease; Ischaemic cardiac events

Indexed keywords

BUDESONIDE; CORTICOSTEROID; PLACEBO;

ANGINA PECTORIS; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HUMAN; HYPOTHESIS; INCIDENCE; ISCHEMIC HEART DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SMOKING; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; BRONCHODILATOR AGENTS; BUDESONIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INHALATION; ISCHEMIA; MALE; PLACEBOS; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS; SMOKING;

EID: 34250187100     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.00128806     Document Type: Article

References (33)

1. World Health Organization. The World Health Report 1998. Life in the 21st Century. A vision for all. Geneva, World Health Organization, 1998.
2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Geneva, NHLBI/WHO report, 2005.
3. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925-931.
4. Agusti A. COPD, a multicomponent disease: implications for management. Respir Med 2005; 99: 670-682.
5. Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005; 2: 8-11.
6. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 2005; 127: 1952-1959.
7. Dankner R, Goldbourt U, Boyko V, Reicher-Reiss H. Predictors of cardiac and non-cardiac mortality among 14,697 patients with coronary heart disease. Am J Cardiol 2003; 91: 121-127.
8. Engström G, Lind P, Hedblad B, et al. Lung function and cardiovascular risk. Relationship with inflammation-sensitive plasma proteins. Circulation 2002; 106: 2555-2560.
9. Anthonisen NR, Connett JE, Enright PL, Manfreda J. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166: 333-339.
10. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912-919.
11. Sin DD, Man SFP. Inhaled corticosteroids in the long-term management of patients with chronic obstructive pulmonary disease. Drugs Aging 2003; 20: 867-880.
12. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74-81.
13. Sin DD, Wu L, Anderson J, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 12: 992-997.
14. Soriano JB, Kiri VA, Pride NB, Vestbo J. Inhaled corticosteroids with/ without long-acting beta-agonists reduce the risk of rehospitalisations and death in COPD patients. Am J Respir Med 2003; 2: 67-74.
15. Tkacova R, Toth S, Sin DD. Inhaled corticosteroids and survival in COPD patients receiving long-term home oxygen therapy. Respir Med 2006; 100: 385-392.
16. Man SFP, Sin DD. Effect of corticosteroids on systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 78-82.
17. Pinto Plata VM, Mifflerova H, Toso JF, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 2006; 61: 23-28.
18. Sin DD, Lacy P, York E, Man SF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 760-765.
19. Broekhuizen R, Wouters; EF, Creutzberg EC, Schols AM. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006; 61: 17-22.
20. Donaldson GC, Seemungal TA, Patel IS, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005; 128: 1995-2004.
21. 1 - a multicentre epidemiological study. Eur Respir J 2005; 26: Suppl. 49, 51s.
22. Kony S, Zureik M, Driss F, Neukirch C, Leynaert B, Neukirch F. Association of bronchial hyperresponsiveness and lung function with C-reactive protein (CRP): a population based study. Thorax 2004; 59: 892-896.
23. Ridker PM. High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. Am Heart J 2004; 148: Suppl. 1, S19-S26.
24. Pauwels RA, Löfdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340: 1948-1953.
25. World Health Organization. 1991 World Health Statistics Annual. Geneva, World Health Organization, 1992.
26. Kiechl S, Werner P, Egger G, et al. Active and passive smoking, chronic infections, and the risk of carotid atherosclerosis. Prospective results from the Bruneck Study. Stroke 2002; 33: 2170-2176.
27. Sin DD, Man SF. Can inhaled steroids mend a broken heart in chronic obstructive pulmonary disease? Eur Respir J 2005; 4: 589-590.
28. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004; 141: 764-770.
29. Wedzicha JA, Seemungal TA, MacCallum PK, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000; 84: 210-215.
30. Calverley PMA. Reducing the frequency and severity of exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004; 1: 161-166.
31. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449-456.
32. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-1303.
33. Johnell O, Pauwels R, Lofdahl CG, et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. Eur Respir J 2002; 19: 1058-1063.